Abstracts tagged "Psoriatic arthritis"

Abstract Number: 1525 • 2019 ACR/ARP Annual Meeting
Safety of Tildrakizumab in Psoriatic Arthritis: An Interim Analysis from a Randomized, Double-blind, Placebo-controlled Phase 2b Trial
Christopher Ritchlin ¹, Vibeke Strand ², Rocco Ballerini ³, Richard C. Chou ⁴, Stephen Rozzo ³, Alan Mendelsohn³ and Arthur Kavanaugh ⁵, ¹Division of Allergy, Immunology and Rheumatology, Center for Musculoskeletal Research, University of Rochester School of Medicine and Dentistry, Rochester, NY, USA, Rochester, NY, ²Division of Immunology/Rheumatology, Stanford University School of Medicine, Palo Alto, CA, USA, Palo Alto, CA, ³Sun Pharmaceutical Industries, Inc., Princeton, NJ, USA, Princeton, NJ, ⁴University at Buffalo School of Medicine and Biomedical Sciences, Buffalo, NY, USA, Buffalo, NY, ⁵University of California, San Diego School of Medicine, La Jolla, CA
Background/Purpose: Tildrakizumab (TIL) is an anti–interleukin-23p19 monoclonal antibody approved by the FDA for treatment of moderate-to-severe plaque psoriasis1,2 and is under investigation for treatment of…
Abstract Number: 1912 • 2019 ACR/ARP Annual Meeting
High Dimensional Flowcytometric Profiling Distinguishes Psoriasis and Psoriatic Arthritis
Michelle Mulder¹, Juul van den Reek ², Elke de Jong ², Bram van Cranenbroek ², Ruben Smeets ², Irma Joosten ², Xuehui He ³, Frank van den Hoogen ¹, Hans Koenen ³ and Mark Wenink ¹, ¹Sint Maartenskliniek, Nijmegen, Netherlands, ²Radboudumc, Nijmegen, Netherlands, ³Radboudumc, Njimegen, Netherlands
Background/Purpose: Psoriasis (Pso) is a common chronic inflammatory skin disease. About 30% of Pso patients develop psoriatic arthritis (PsA), a chronic inflammation of joints and…
Abstract Number: 2452 • 2019 ACR/ARP Annual Meeting
The Performance of a Multi-marker Genetic Test to Identify Patients with Psoriatic Arthritis Among Psoriasis Patients
Lihi Eder¹, Quan Li ², Dana Jerome ³, Chandra Farrer ⁴, Proton Rahman ⁵ and Tanya N. Burry ⁶, ¹Women’s College Hospital and the Department of Medicine, University of Toronto, Toronto, Canada, ²Toronto Western Hospital, Toronto, Canada, ³University of Toronto, Toronto, ⁴University of Toronto, Toronto, Canada, ⁵Memorial University, Newfoundland, NL, Canada, ⁶Memorial University, St. Johns, Canada
Background/Purpose: Improved understanding of the complex genetic architecture of PsA along with the reduction in the cost of genetic testing provide an opportunity to assess…
Abstract Number: 2473 • 2019 ACR/ARP Annual Meeting
Implementing the Psoriatic Arthritis Disease Activity Score (PASDAS) in Routine Clinical Practice: (im)possible?
Michelle Mulder¹, Alfons den Broeder ¹, Berbke van Ginneken ¹, Elien Mahler ¹, Frank van den Hoogen ¹, Johanna Vriezekolk ¹ and Mark Wenink ¹, ¹Sint Maartenskliniek, Nijmegen, Netherlands
Background/Purpose: Psoriatic arthritis (PsA) is a heterogeneous disease, with involvement of at least five health domains: peripheral joint disease, enthesitis, dactylitis, axial involvement, and skin…
Abstract Number: 2493 • 2019 ACR/ARP Annual Meeting
IL-6 and TNF-α Influence on Clinical Manifestations, Activity and Comorbidity in Psoriatic Arthritis Patients
Maria Elisa Acosta¹, Luis Gomez-Lechon ¹, Guadalupe Manzano Canabal ¹, Olga Compan ², Cristina Hidalgo ³, Olga Martinez ¹, Ana Turrión ¹, Javier del Pino ¹ and Carlos Montilla ¹, ¹Hospital Clínico Universitario de Salamanca, Salamanca, Spain, ²Hospital Clinico Universitario de Salamanca, SALAMANCA, Spain, ³Hospital Clínico Universitario de Salamanca, Salamanca, Castilla y Leon, Spain
Background/Purpose: The activation of the Th-1 and Th-17 lymphocytes response seems to be one of the causes associated with PsA onset. During this process cytokines…
Abstract Number: 2717 • 2019 ACR/ARP Annual Meeting
Long-term Outcome of Juvenile-onset Psoriatic Arthritis
Devy Zisman¹, Tal Gazitt ², Amir Haddad ², Idit Lavi ², Snezana Barac ³, Vinod Chandran ⁴, Jan Dutz ⁵, Lihi Eder ⁶, James T Elder ⁷, Richard Hayday ⁸, Proton Rahman ⁹, Christopher Ritchlin ¹⁰, Sherry Rohekar ¹¹, Cheryl F. Rosen ¹² and Dafna Gladman ¹³, ¹Carmel Hospital and Ruth and Bruce Rappaport Faculty of Medicine, Technion, Israel, Haifa, Israel, ²Carmel Hospital, Haifa, Israel, ³Winnipeg Clinic, Winnipeg, MB, Canada, ⁴Department of Medicine, University of Toronto,Centre for Prognosis Studies in the Rheumatic Diseases, Toronto Western Hospital, Toronto, ON, Canada, ⁵University of British Columbia, Vancuver, BC, Canada, ⁶Women’s College Hospital and the Department of Medicine, University of Toronto, Toronto, Canada, ⁷University of Michigan Medical School,, Ann Arbor, MI, ⁸University of Manitoba, Winnipeg, MB, Canada, ⁹Memorial University, Newfoundland, NL, Canada, ¹⁰Division of Allergy, Immunology and Rheumatology, Center for Musculoskeletal Research, University of Rochester School of Medicine and Dentistry, Rochester, NY, USA, Rochester, NY, ¹¹Western University, London, ON, Canada, ¹²Division of Dermatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ¹³Toronto Western Hospital, Toronto, Canada, Toronto, ON, Canada
Background/Purpose: There is no consensus in the literature with regard to the features and long-term prognosis of psoriatic arthritis (PsA) starting in childhood (jPsA). We…
Abstract Number: 436 • 2019 ACR/ARP Annual Meeting
Poor Concordance Between Remission Judged by Physicians and a Patient-Acceptable Symptom State in Psoriatic Arthritis
Rubén Queiro¹, Estefania Pardo ¹, Lilyan Charca ¹, Sara Alonso ¹, L. Arboleya ² and Mercedes Alperi-López ¹, ¹Hospital Universitario Central de Asturias, Oviedo, Spain, ²Hospital Central Asturias, OViedo
Background/Purpose: Both the evaluation of disease activity in psoriatic arthritis (PsA) and the determination of the impact of the disease on patients' lives are subjects…
Abstract Number: 1085 • 2019 ACR/ARP Annual Meeting
Probiotic Use and Psoriatic Arthritis Disease Activity
Madison Grinnell¹, Kristin Wipfler ², Alexis Ogdie ³ and Kaleb Michaud ⁴, ¹University of Nebraska College of Medicine, OMAHA, NE, ²FORWARD, The National Databank for Rheumatic Diseases, Wichita, KS, ³Department of Medicine and Rheumatology and Department of Epidemiology and Biostatistics, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, ⁴University of Nebraska Medical Center, Omaha, NE
Background/Purpose: Probiotics have been hypothesized to mediate inflammation through gut microbiome modulation, and growing evidence has suggested that our intestinal gut microbiome may play a…
Abstract Number: 1481 • 2019 ACR/ARP Annual Meeting
Real-World Use of Apremilast in Combination with Biologic Therapy in Patients with Psoriatic Arthritis: Findings from the Corrona Psoriatic Arthritis/Spondyloarthritis Registry
Alexis Ogdie¹, Mei Liu ², Meghan Glynn ³, Kelechi Emeanuru ², Leslie Harrold ⁴, Sven Richter ⁵, Benoit Guerette ⁵ and Philip Mease ⁶, ¹Department of Medicine and Rheumatology and Department of Epidemiology and Biostatistics, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, ²Corrona, LLC, Waltham, MA, ³Corrona, LLC, Waltham, ⁴Corrona, LLC and University of Massachusetts Medical School, Worcester, MA, ⁵Celgene Corporation, Summit, ⁶Swedish Medical Center/Providence St Joseph Health, and University of Washington, Seattle, WA
Background/Purpose: Apremilast (APR), an oral phosphodiesterase 4 inhibitor, demonstrated efficacy in adult patients with active PsA despite prior use of csDMARDs and/or biologics in phase…
Abstract Number: 1531 • 2019 ACR/ARP Annual Meeting
ALPN-101, a First-in-Class Dual ICOS/CD28 Antagonist, Suppresses Key Effector Mechanisms Underlying Rheumatoid and Psoriatic Arthritis
Lawrence Evans¹, Stacey Dillon ¹, Katherine Lewis ¹, Susan Bort ¹, Erika Rickel ¹, Jing Yang ¹, Martin Wolfson ¹, Sherri Mudri ¹, Kayla Susmilch ¹, Steven Levin ¹, Sean MacNeil ¹, Mark Rixon ¹, Jan Hillson ², Stanford Peng ¹ and Kristine Swiderek ¹, ¹Alpine Immune Sciences, Seattle, WA, ²Alpine Immune Sciences, Seattle, WI
Background/Purpose: ALPN-101 is an Fc fusion protein of a human inducible T cell costimulator ligand (ICOSL) variant immunoglobulin domain (vIgDTM) designed to simultaneously inhibit the…
Abstract Number: 2098 • 2019 ACR/ARP Annual Meeting
Distinctive Pattern of LTBI Screening Parameters in Ankylosing Spondylitis (AS) and Psoriatic Arthritis (PsA) in Endemic Areas
Andrea Shimabuco ¹, Ana Cristina de Medeiros Ribeiro ², Renata Miossi ³, Karina Bonfiglioli ³, Julio Cesar Bertacini Moraes ³, Celio Gonçalves ³, Percival Sampaio-Barros ³, Claudia Goldenstein-Schainberg ³, Fernando Henrique Souza ³, Leandro Prado ³, Michelle Remião Ugolini-Lopes ⁴, Emily Yuki ⁵, Eloisa Bonfa ⁶ and Carla Gonçalves Schahin Saad³, ¹Hospital das Clinicas da Faculdade de Medicina da Universidade de São Paulo, Sao Paulo, Brazil, ²Hospital das Clinicas da Faculdade de Medicina da Universidade de Sao Paulo, Sao Paulo, Sao Paulo, Brazil, ³Hospital das Clinicas da Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil, ⁴Rheumatology Division - Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo (FMUSP), Sao Paulo, Sao Paulo, Brazil, ⁵Rheumatology Division, Hospital das Clinicas, Faculdade de Medicina da Universidade de Sao Paulo (HCFMUSP), Sao Paulo, Brazil., São Paulo, Brazil, ⁶Rheumatology Division, Hospital das Clinicas, Faculdade de Medicina da Universidade de Sao Paulo (HCFMUSP), Sao Paulo, Brazil., Sao Paulo, Sao Paulo, Brazil
Background/Purpose: Despite late tuberculosis infection (LTBI) screening before anti-TNF treatment, TB reactivation/new exposure in endemic areas remains a relevant problem. The specific analysis of Ankylosing…
Abstract Number: 2453 • 2019 ACR/ARP Annual Meeting
Static and Longitudinal Construct Validity of PROMIS CAT and Profile29 for Assessing Pain Interference, Physical Function and Fatigue in Psoriatic Arthritis
Ana-Maria Orbai¹, Jamie Perin ², Albert W Wu ³, Katherine C. Smith ⁴ and Clifton Bingham ⁵, ¹Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ²Johns Hopkins University School of Public Health, Department of International Health, Baltimore, ³Johns Hopkins University Bloomberg School of Public Health, Department of Health Policy and Management, Baltimore, MD, ⁴Johns Hopkins University Bloomberg School of Public Health, Department of Health, Behavior and Society, Baltimore, MD, ⁵Johns Hopkins University, Baltimore, MD
Background/Purpose: Pain, physical function and fatigue are outcomes reported as having the greatest importance to people with psoriatic arthritis (PsA)1,2. We assessed these outcomes in…
Abstract Number: 2474 • 2019 ACR/ARP Annual Meeting
Impact of Multidomain Disease Presentations on Overall Disease Burden Among Patients with Psoriatic Arthritis: Results from the Corrona Psoriatic Arthritis/Spondyloarthritis (PsA/SpA) Registry
Alexis Ogdie¹, Peter Hur ², Mei Liu ³, Sabrina Rebello ³, Robert McLean ³, Blessing Dube ³, Meghan Glynn ⁴ and Philip Mease ⁵, ¹Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, ²Novartis Pharmaceuticals Corporation, East Hanover, NJ, ³Corrona, LLC, Waltham, MA, ⁴Corrona, LLC, Waltham, ⁵Swedish Medical Center/Providence St Joseph Health, and University of Washington, Seattle, WA
Background/Purpose: Psoriatic arthritis (PsA) is a chronic inflammatory disease with heterogeneous presentations that may involve peripheral arthritis, axial disease, enthesitis, dactylitis, and psoriatic skin and…
Abstract Number: 2496 • 2019 ACR/ARP Annual Meeting
Serum Metabolomic Analysis of Psoriatic Arthritis Using Solid Phase Microextraction – Liquid Chromatography – High-Resolution Mass Spectrometry Identifies Putative Disease Activity Markers
Vinod Chandran¹, Nikita Looby ², Nathaly Reyes-Garces ², Rohan Machhar ³, Miao Yu ², Anna Roszkowska ², Janusz Pawliszyn ² and Vathany Kulasingam ⁴, ¹University Health Network, University of Toronto, Toronto, Canada, ²University of Waterloo, Waterloo, ON, Canada, ³Krembil Research Institute, University Health Network, Toronto, Canada, ⁴University of Toronto, Toronto, ON, Canada
Background/Purpose: Disease activity in psoriatic arthritis (PsA) is often difficult to assess but drives treatment decisions, joint damage and long-term outcomes. We aimed to identify…
Abstract Number: 2743 • 2019 ACR/ARP Annual Meeting
Characterizing the Epigenomic Landscape of Psoriasis Patients Destined to Develop Psoriatic Arthritis
Remy Pollock¹, Rohan Machhar ¹, Vinod Chandran ² and Dafna Gladman ³, ¹Krembil Research Institute, University Health Network, Toronto, Canada, ²University Health Network, University of Toronto, Toronto, Canada, ³Toronto Western Hospital, Toronto, Canada, Toronto, ON, Canada
Background/Purpose: Approximately 30% of psoriasis patients develop psoriatic arthritis (PsA), an inflammatory musculoskeletal disease, usually after psoriasis onset. A large proportion of individuals with PsA…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].